Shira N. Dinner

Shira N. Dinner

Hematology | Oncology
675 N St Clair St Ste 21-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.

Journal: European journal of haematology
Published: May 27, 2026

Challenges in the treatment of adolescent and young adult acute lymphoblastic leukemia: A comprehensive review.

Challenges in the treatment of adolescent and young adult acute lymphoblastic leukemia: A comprehensive review.

Journal: Blood reviews
Published: February 18, 2026

Social Genomic Mechanisms of Health Disparities Among Adolescent/Young Adult Survivors of Hodgkin and Non-Hodgkin Lymphoma: ECOG-ACRIN E.

Social Genomic Mechanisms of Health Disparities Among Adolescent/Young Adult Survivors of Hodgkin and Non-Hodgkin Lymphoma: ECOG-ACRIN E.

Journal: Journal of adolescent and young adult oncology
Published: November 21, 2025

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

Journal: The Lancet. Haematology
Published: November 17, 2025

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 30, 2025

Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.

Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.

Journal: JACC. CardioOncology
Published: August 18, 2025

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.

Journal: Blood advances
Published: July 23, 2025

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.

Journal: Leukemia & lymphoma
Published: July 09, 2025

Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15).

Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15).

Journal: Cancers
Published: May 19, 2025

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Journal: Blood advances
Published: April 07, 2025

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.

Journal: Blood neoplasia
Published: January 22, 2025

B-ALL in a 21-year-old male with X-linked agammaglobulinemia (XLA): a case report and review of B-cell malignancies in XLA.

B-ALL in a 21-year-old male with X-linked agammaglobulinemia (XLA): a case report and review of B-cell malignancies in XLA.

Journal: Leukemia & lymphoma
Published: December 13, 2024
Showing 1-12 of 61

Last Updated: 09/26/2026